{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015646",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015646_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"acalabrutinib\" outputclass=\"int-drug\">acalabrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   -containing antacids   are predicted to   decrease   the exposure to   oral   acalabrutinib .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acalabrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015647",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015647_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"bosutinib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/bosutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33920\">bosutinib</xref></ph> should be taken at least 12 hours before antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   -containing antacids   are predicted to   decrease   the absorption of   oral   bosutinib .  Manufacturer advises  bosutinib  should be taken at least 12 hours before antacids .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015648",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015648_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   -containing antacids   are predicted to   decrease   the exposure to   oral   dasatinib .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015649",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015649_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"erlotinib\" outputclass=\"int-drug\">erlotinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"erlotinib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/erlotinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5529\">erlotinib</xref></ph> should be taken 2 hours before or 4 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   -containing antacids   are predicted to   decrease   the absorption of   oral   erlotinib .  Manufacturer advises  erlotinib  should be taken 2 hours before or 4 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erlotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015650",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015650_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"gefitinib\" outputclass=\"int-drug\">gefitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   -containing antacids   are predicted to   decrease   the exposure to   oral   gefitinib .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gefitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015651",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015651_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">ketoconazole</ph>. <ph outputclass=\"int-action\">Manufacturer advises separating administration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   decreases   the absorption of   ketoconazole .  Manufacturer advises separating administration .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015652",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015652_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"lapatinib\" outputclass=\"int-drug\">lapatinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   -containing antacids   are predicted to   decrease   the absorption of   oral   lapatinib .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lapatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015653",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015653_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">Sodium bicarbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Sodium bicarbonate   decreases   the concentration of   lithium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015654",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015654_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">Sodium bicarbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"methenamine\" outputclass=\"int-drug\">methenamine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sodium bicarbonate   is predicted to   decrease   the efficacy of   methenamine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methenamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015655",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015655_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"neratinib\" outputclass=\"int-drug\">neratinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 3 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   -containing antacids   are predicted to   decrease   the exposure to   oral   neratinib .  Manufacturer advises separate administration by at least 3 hours .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Neratinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015656",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015656_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">affect</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   -containing antacids   might   affect   the exposure to   oral   nilotinib .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015657",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015657_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"pazopanib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/pazopanib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5542\">pazopanib</xref></ph> should be taken 1 hour before or 2 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   -containing antacids   might   decrease   the absorption of   oral   pazopanib .  Manufacturer advises  pazopanib  should be taken 1 hour before or 2 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015658",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015658_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"rilpivirine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/rilpivirine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3830\">rilpivirine</xref></ph> should be taken 4 hours before or 2 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   -containing antacids   are predicted to   decrease   the exposure to   oral   rilpivirine .  Manufacturer advises  rilpivirine  should be taken 4 hours before or 2 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rilpivirine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015659",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2#bnf_i1643858015659_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-heading-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"sotorasib\" outputclass=\"int-drug\">sotorasib</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"sotorasib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/sotorasib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP223696\">sotorasib</xref></ph> should be taken 4 hours before or 10 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   is predicted to   decrease   the exposure to   oral   sotorasib .  Manufacturer advises  sotorasib  should be taken 4 hours before or 10 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotorasib</title>"
					}
				}
			],
			"hasSearchLabel": " Sodium bicarbonate  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/sodium-bicarbonate-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Sodium bicarbonate </title>"
			},
			"rdfs:label": "sodium bicarbonate"
		}
	]
}